The drug exhibits a multimodal mechanism. It not only reverses chemoresistance and halts tumor growth but also 'turns cold tumors hot' by forcing cancer cells to display markers that make them visible to the immune system. This dual action of direct attack and immune activation creates a powerful synergistic effect.

By simultaneously targeting dozens of functionally unrelated survival genes across different chromosomes, Nuago's therapy makes it statistically improbable for cancer cells to mutate and develop escape routes. This multi-pronged attack from a single drug construct is a core advantage over therapies that cancer can evolve around.

To reduce risk, Nuago prioritizes cancers based on two criteria: high unmet medical need and the existence of clinically validated delivery methods for that specific tissue. This strategy separates their novel drug science from novel delivery science, allowing them to focus resources on proving their mechanism without inventing a delivery system.

Cancer cells down-regulate microRNAs to enable growth. This biological shift creates an opening for Nuago's therapy to access the cell's machinery. Healthy cells, with high microRNA expression, naturally block the therapy. This provides inherent selectivity, a huge therapeutic window, and minimal toxicity by design of fundamental biology.

The therapy’s targets are fundamental survival genes conserved from worms to humans. This deep biological foundation makes the treatment 'cancer-agnostic,' effective regardless of tumor origin, subtype, or the patient's genetic background. The company has successfully killed 66 different tumor types across seven species.

Unlike therapies targeting a single cell death pathway like apoptosis, Nuago's DICE (Death Induced by Survival Gene Elimination) triggers a systemic collapse. By silencing numerous survival genes, it disrupts core cellular networks, activating all 22 known molecular cell death pathways at once, making it impossible for the cancer cell to escape.

Traditional targeted cancer therapies inhibit or 'cool down' overactive pathways, like pumping brakes on a runaway car. Delpha Therapeutics employs a counterintuitive 'activation lethality' approach, further over-activating pathways to 'overheat the engine' and cause catastrophic failure in cancer cells—a fundamentally opposite but highly effective strategy.

Cancer's primary "trick" is adaptation. Immuneering's deep cyclic inhibition prevents this by intermittently shutting down signaling pathways. The cancer lets its guard down during the "off" cycle and is ambushed again the next day, preventing it from learning to develop durable resistance.

Nuago leverages the 'seed-mediated off-target effect'—a bug for single-gene therapies—as a feature. Their short RNAs use a six-nucleotide seed to promiscuously target hundreds of survival and oncogenes, achieving a broad therapeutic effect where 'off-target' is the entire point, making unintended effects impossible.